key: cord-0921389-ut28u8gu
authors: Parzych, Elizabeth; Weiner, David B.
title: Nucleic Acid Approaches to Antibody-based Therapeutics for COVID-19: A Perspective
date: 2020-07-03
journal: J Allergy Clin Immunol
DOI: 10.1016/j.jaci.2020.06.022
sha: cb98341c4c2e896e311b38ba0bcf6f9bbdb0408e
doc_id: 921389
cord_uid: ut28u8gu

nan

The rapid emergence and spread of sudden acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has resulted in a staggering pandemic. Infection with SARS-CoV-2 results in an array of symptoms that range from minor and self-limiting (80% of cases) to severe (15-20%), with an unacceptably high fatality rate (0.5-4%) (1) . Severe disease often leads to an overproduction of proinflammatory mediators that exacerbate disease, impacting progression and clinical outcome (reviewed in (2) ). In addition to the urgent development of vaccines and antiviral drugs, alternative therapeutics that facilitate viral control and limit immunopathology are of interest. Monoclonal antibodies (mAb) are important biologics which bypass the adaptive immune system and are being deployed for the treatment of various infectious diseases, inflammation-driven autoimmune disorders and cancers. Limited studies suggest that the passive administration of convalescent SARS-CoV-2 sera may be associated with alleviation of severe disease in some patients, supporting the pursuit of antibody-based approaches for SARS-CoV-2.

Efforts are currently focused on two major categories of mAb products-antiviral and antiinflammatory-to address the major drivers of COVID-related disease (Figure 1) . However, achieving the rapid production, scalability and distribution sufficient to combat a pandemic such as COVID-19 using the traditional mAb platform represents a challenge, particularly if readministration or antibody cocktails are required for optimal efficacy. We have observed how quickly nucleic acid products can be advanced to the clinic with the development of novel vaccines for COVID-19 ((3); NCT04283461; NCT04336410). Similarly, nucleic acid approaches represent a potential alternative method for mAb delivery as well as compelling tools for the affordable and rapid in vivo evaluation of mAb-based therapeutic due to their simplicity, ease of production, scalability, conceptual safety and established potency in preclinical models.

Due to significant advancement over recent years, nucleic acid-based technologies hold increased potential to provide rapid and consistent antibody-mediated protection while avoiding the technical challenges associated with recombinant mAb production. 

Antiviral antibodies typically target surface-exposed antigens to inhibit viral infection and/or progression (Figure 1) . Though SARS-CoV-2 contains several potential surface targets, the focus remains largely on the highly conserved coronavirus spike (S) protein, which mediates viral attachment and invasion via engagement with the host ACE-2 receptor. Antibodies directed against the S protein of SARS-CoV, a closely related coronavirus that previously caused a deadly outbreak in humans, conferred protection in vivo. One such neutralizing antibody (nAb), mAb CR3022, cross-reacts with a unique epitope in the receptor binding domain (RBD) of the SARS-CoV-2 Spike (S) protein (7, 8) . As an exemplative use of this technology against SARS-CoV-2, CR3022 sequences were modified and optimized as previously described (9) to generate a novel DMAb encoding human CR3022 which was successfully expressed in mice ( Figure 2D) . Sera harvested D7 post-administration exhibited potent binding to the SARS-CoV-2 S1 protein ( Figure 2E) . Studies of additional important SARS-CoV-2 antibodies using nucleic acid platforms will be informative.

In addition to antiviral tools, there is a need to develop therapies to reduce SARS-CoV-2mediated immunopathology. Severe disease is associated with significant upregulation of numerous proinflammatory cytokines and chemokines including IL-6, IL-1β, TNFα, IL-2, IL-8, IL-17, G-CSF, GM-CSF, IP10, MCP1, MIP1α (reviewed in (2)). Additionally, overactivation of the complement system is thought to contribute to this pathology. Immunotherapy with mAbs that target such inflammatory markers are of interest. The potential benefit of mAbs targeting the IL-6 pathway (Anti-IL-6/ IL-6R) as a therapy for critically ill COVID patients is under investigation.

Similar to delivery of pathogen-targeting DMAbs, studies have demonstrated the ability to administer immune-modulating antibodies with potent in vivo effects (reviewed in (4)).

Accordingly, we optimized inserts encoding anti-IL-6 and anti-IL-6R DMAbs and administered them in vivo. As shown, anti-IL-6 ( Figure 2F ) and anti-IL-6R ( Figure 2G ) DMAbs were successfully expressed, able to bind their respective targets and inhibited IL-6 activation in vitro (data in progress).

As rapid response tools, nucleic acid approaches can be used to generate, screen, compare, down-select and develop potent biologics in vivo. Furthermore, the pursuit of mAbs-based products able to mitigate disease via unique and complementary mechanisms to enhance treatment efficacy is of interest. Gene delivery approaches allow for these types of combination studies in which antibody cocktails are rapidly evaluated and optimized for increased potency over corresponding monoclonal formulations; this has been validated for HIV-targeting antibody combinations using the DMAb platform (10). This represents a tailored, rapid and possibly important approach to therapeutic development for SARS-CoV-2 and future outbreaks.

The astonishing pace with which the COVID-19 pandemic has spread across the globe emphasizes the need to have strategies in place for the rapid development of novel biologics including of vaccines and immunotherapeutics. The speed at which nucleic acid vaccines entered and continue to advance through the clinic supports the use of these approaches in generating additional therapeutics to combat global outbreaks. Advancing such strategies to clinical trials will help define their feasibility to serve as potential alternatives or supplements to traditional mAb therapy. Importantly, these tools could improve the accessibility of such impactful mAb-based biologics to larger global populations. 

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

COVID-19: immunopathology and its implications for therapy

Rapid development of a synthetic DNA vaccine for COVID-19

DNA vaccines: prime time is now

A lipidencapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection

Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model

In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1-neutralizing activity